About Boltii Diagnostics Inc
Our Mission
Boltii Diagnostics strives to help eliminate cervical cancer by making high‑quality HPV screening simple, affordable, and accessible to everyone—regardless of geography, infrastructure, or income. We believe no woman should die from a disease that is preventable with timely screening and treatment.
Our mission is deeply rooted in global health equity. We are proud to align our efforts with the 2025 UN General Assembly Political Declaration on NCDs, which established a historic mandate for the elimination of HPV-related cancers. By prioritizing expanded access to HPV screening, we are helping turn the UN’s 2030 global health targets into a local reality.
Our work is driven by a single goal: to translate cutting‑edge molecular biology into practical diagnostic tools that can be deployed at global scale.
The Global Challenge of Cervical Cancer
Cervical cancer remains one of the leading causes of cancer death among women worldwide. Each year, more than 600,000 new cases are diagnosed, and over 300,000 women die from the disease—one life lost unnecessarily every two minutes. Over 90% of these deaths occur in low‑ and middle‑income countries (LMICs), where access to effective screening is limited.
Persistent infection with high‑risk human papillomavirus (HPV) is the necessary cause of cervical cancer. While HPV vaccination and screening together can prevent the vast majority of cases, screening programs in many regions are constrained by cost, infrastructure, logistics, and complexity.
The WHO Cervical Cancer Elimination Strategy
The World Health Organization (WHO) has set a bold but achievable global target to eliminate cervical cancer as a public health problem. The strategy is built on three pillars:
-
90% of girls fully vaccinated against HPV by age 15
-
70% of women screened with a high‑performance test by ages 35 and 45
-
90% of women with cervical disease receiving appropriate treatment
High‑performance HPV DNA testing is the cornerstone of this strategy. However, existing molecular tests are often expensive, equipment‑intensive, slow, and dependent on cold‑chain logistics—making widespread implementation difficult in resource‑limited settings.
Limitations of Current HPV Screening Technologies
Today’s commercial HPV tests are dominated by PCR‑based systems and signal‑amplification assays that were designed for centralized laboratories. While clinically effective, these platforms typically require:
-
Sophisticated thermal cyclers and analyzers
-
Continuous cold‑chain storage and transport
-
Batch processing with hours‑long turnaround times
-
High capital and per‑test costs
As a result, many screening programs struggle to reach the women who are most at risk. The gap is not scientific—it is operational.
TrueLAMP™: A New Molecular Engine for Global Screening
Boltii Diagnostics developed TrueLAMP™, a next‑generation isothermal amplification technology engineered to overcome the historical limitations of conventional LAMP.
Traditional LAMP is fast and simple, but its adoption has been hindered by non‑specific amplification and false positives. TrueLAMP solves this problem through a proprietary polymerase formulation that selectively suppresses non‑specific primer amplification—delivering high specificity with a simple visual readout.
Designed for Real-World Screening:
-
Simple: No complex instrumentation required; runs in a simple 65 °C oven or water bath
-
Stable: Provides preloaded 8-strip reaction tubes containing required dried reagents
-
Easy workflow: Add sample → incubate → read results
-
Robust: Reliable results without strict read-time constraints, readable from 30 minutes to overnight
-
Rapid: Delivers clear, visual diagnostic results in as little as 30–45 minutes
-
Affordable: Low manufacturing and deployment costs make it ideal for resource-limited settings
-
Accessible: Paired with self-sampling and mail-in options, it brings HPV testing to anyone, anywhere
Bridging Performance and Access
Boltii’s HPV platform is designed to combine the clinical rigor of high-performance molecular testing with the operational simplicity required for decentralized and point-of-care use.
By reducing dependence on complex equipment, cold-chain logistics, and centralized laboratories, TrueLAMP-powered diagnostics can expand access to reliable HPV screening—bringing prevention closer to the communities that need it most.
Our Commitment
Boltii Diagnostics is committed to rigorous validation, transparency, and collaboration with clinicians, researchers, and global health partners to achieve the ultimate goal of eradicating cervical cancer.
We believe innovation in molecular diagnostics is not just about better chemistry—it is about impact at scale. Together, we aim to make cervical cancer a preventable disease everywhere.
